Abstract In a mature (weight neutral) animal, an increase in muscle mass only occurs when the muscle is loaded sufficiently to cause an increase in myofibrillar protein balance. A tight relationship between muscle hypertrophy, acute increases in protein balance, and the activity of the mechanistic target of rapamycin complex 1 (mTORC1) was demonstrated 15 years ago. Since then, our understanding of the signals that regulate load-induced hypertrophy has evolved considerably. For example, we now know that mechanical load activates mTORC1 in the same way as growth factors, by moving TSC2 (a primary inhibitor of mTORC1) away from its target (the mTORC activator) Rheb. However, the kinase that phosphorylates and moves TSC2 is different in the two processes. Similarly, we have learned that a distinct pathway exists whereby amino acids activate mTORC1 by moving it to Rheb. While mTORC1 remains at the forefront of loadinduced hypertrophy, the importance of other pathways that regulate muscle mass are becoming clearer. Myostatin, is best known for its control of developmental muscle size. However, new mechanisms to explain how loading regulates this process are suggesting that it could play an important role in hypertrophic muscle growth as well. Last, new mechanisms are highlighted for how b2 receptor agonists could be involved in load-induced muscle growth and why these agents are being developed as non-exercisebased therapies for muscle atrophy. Overall, the results highlight how studying the mechanism of load-induced skeletal muscle mass is leading the development of pharmaceutical interventions to promote muscle growth in those unwilling or unable to perform resistance exercise.
The regulation of tissue size is dictated by the balance between the rates of protein synthesis and degradation [1] . More specifically, it is the balance of the synthesis and degradation of functional and structural proteins within the cell that determines tissue size. Consequently, in muscle a net positive or net negative myofibrillar protein balance results in hypertrophy or atrophy, respectively. In healthy adults, rates of myofibrillar protein synthesis fluctuate between periods of net positive (after protein feeding) and net negative (fasting) balance, such that the change in muscle mass over time is, broadly speaking, very small [2] . While both rates of myofibrillar protein synthesis and breakdown fluctuate during anabolic and catabolic conditions, using our current methods the rate of protein synthesis appears more dynamic than that of protein breakdown, ultimately suggesting skeletal muscle mass is primarily dictated by the regulation of muscle protein synthesis [3] . There is also a fallacy in the field that decreasing the rate of degradation would always increase muscle mass. In some cases this is true [4, 5] . However, it is now clear that some forms of protein degradation actually are necessary to drive protein synthesis and improve both muscle size and quality [6, 7] .
Skeletal muscle is a plastic tissue that rapidly adapts to its mechanical environment [8] . Increased load across a muscle, such as from strength (resistance) exercise or heavy work, results in a compensatory increase in muscle size and strength. This increase in size occurs largely from the growth of existing cells (hypertrophy) rather than an increase in cell number (hyperplasia) [9] . Mechanical loading also results in strong adaptive responses in a host of other tissues including bone [10] , tendon [11] , and the extracellular matrix in muscle [12] , protecting these tissues against future injury. Conversely, tissue atrophy occurs with the introduction of catabolic stimuli including dietary protein withdrawal [13] , mechanical unloading [14, 15] , or during disease/injury states [16] . The ability of skeletal muscle to hypertrophy in response to load will be the focus of this review. For more information on atrophy, the reader is directed to the following excellent reviews on the topic [17, 18] .
Bigger and stronger skeletal muscles improve both the quality and length of our lives [19] [20] [21] . Currently, resistance training is the only bona fide intervention to increase muscle mass that can be implemented on a population-wide basis. Despite its wide-ranging benefits [22] , resistance training is under-prescribed [23] and regularly practiced only by a small minority of individuals. Further, there are a host of situations (e.g., injury, illness, bed rest, limited accessibility to facilities, social constraints) that preclude many individuals from resistance training. Therefore, adjunct therapies to increase or preserve muscle mass would have a major impact on population health and wellbeing. Given this context, the goal of the present review is to highlight both established and emerging molecular mechanisms that regulate load-induced skeletal muscle hypertrophy and might be exploited for developing new interventions designed to increase muscle mass.
Signals Controlling Load-Induced Skeletal Muscle Hypertrophy

Load
The most important signal for muscle growth in a mature (weight neutral) individual is the load across the muscle. This was best demonstrated in a series of experiments performed by Wong and Booth in the late 1980s [24] [25] [26] .
In these experiments, all of the hindlimb muscles of the right leg of a rat were electrically stimulated. Because of the greater mass in the posterior compartment, the ankle would plantar flex resulting in high load lengthening contractions on the anterior compartment muscles (the tibialis anterior (TA) and extensor digitorum longus) and low load shortening contractions in the muscles of the posterior compartment (gastrocnemius (GTN), plantaris, and soleus).
Ten weeks of training without an external load resulted in hypertrophy of the TA without a change in muscle size in the GTN [26] . The exact same stimulation protocol, only this time adding a weight to resist plantar flexion, resulted in significant growth of both the TA and GTN (Fig. 1) . Since the only difference between the groups was the external load, the most obvious conclusion is that load is the key to muscle hypertrophy. Further analysis of this data set can provide other insights, including the fact that power is not important for muscle hypertrophy. This conclusion comes from comparing TA muscle hypertrophy from the non-weighted and weighted group (Fig. 1) . In both cases, the hypertrophy is the same. That makes sense if load is the stimulus for hypertrophy since the stretch of the TA by the GTN provides the load. However, the addition of load to the foot would slow the rate at which that load was developed, resulting in a decrease in the power applied to the TA muscle. Since the hypertrophy of the TA is the same with or without an external load [26] , power cannot be the stimulus for muscle growth.
The fact that the load across the muscle is important for muscle hypertrophy in adult animals is widely accepted. However, recent studies showing that both high and low load resistance exercise could drive muscle protein synthesis and hypertrophy to the same degree [27, 28] and that blood flow restriction can drive hypertrophy at low loads [29, 30] raised some questions about the role of load in muscle hypertrophy. Briefly, Prof. Phillips and his group had subjects perform resistance exercise with either 90 % of their 1 repetition maximum (1RM) or 30 % of 1RM. For Fig. 1 The effect of load on muscle hypertrophy. The increase in muscle mass following 10-week resistance exercise in CON, animals that received no stimulation; no weight, animals that exercised without an external weight to prevent dorsiflexion; and weight, animals where dorsiflexion was resisted by an external load just less than maximal isometric load. Adapted from [26] the groups performing 30 % 1RM, the subjects were further divided into two groups: one that was matched for the work performed by the 90 % 1RM group, and another that continued to lift 30 % 1RM to failure. Interestingly, mixed muscle protein synthesis increased the same amount in the 90 and 30 % to failure groups, whereas in the 30 % workmatched group a smaller increase in protein synthesis was observed [27] . When they performed a follow-up training study using either a high or low load to failure they found that the amount of muscle hypertrophy was the same in both groups [28] . So, how can this finding be juxtaposed with the loading findings in animals? The simplest explanation is that during human resistance exercise motor units are recruited based on the load: low loads need only small motor units (fewer muscle fibers), whereas high loads require more and bigger motor units (more fibers). However, as an individual progresses toward failure, more motor units are recruited until at failure all of the motor units within the muscle are activated in an attempt to lift the weight. Therefore, at failure all fibers within the working muscle are loaded. In animal studies, electrical stimulation overrides this issue by depolarizing and activating all of the fibers directly and therefore the effect of load is more obvious. Taken together, these data suggest that the load across the muscle is the primary stimulus for skeletal muscle hypertrophy and the only way to provide load across all fibers in humans is to perform exercise to failure.
Hormones
The first molecular regulators of skeletal muscle mass identified were hormones such as testosterone [31] . The fascinating history of the discovery of the hormone testosterone covers more than a 1000 years [32] . However, for muscle physiologists the role of this hormone in the control of muscle size and strength starts just over a century ago. In 1889, a French physiologist named Charles Edouard BrownSequard claimed that daily injections of an extract isolated from the testes of dogs and guinea pigs had increased the strength of the 72-year-old physician/scientist [33] . Even though it is likely that this was nothing more than a placebo effect, his report started more than a century of work on what would be called hormones and their effect on skeletal muscle size and strength. With the isolation and production of synthetic testosterone in 1935 [32] , scientists were able to inject testosterone propionate and show for the first time that this hormone could lead to ''a definite hypertrophy'' of all of the muscles in the body [31] . By 1942 [34] , this had been shown in young men, starting more than 70 years of testosterone use to improve muscle size, strength, and performance [33] . However, it is important to note that testosterone affects developmental growth far more than hypertrophic growth.
For example, women, who have approximately one-tenth the testosterone of men, have developmentally smaller muscles [35] . However, women show the same relative amount of muscle hypertrophy as men following 16 weeks of strength training [35] . Further, even though muscle mass is lost during androgen deprivation therapy, resistance exercise is still able to produce skeletal muscle hypertrophy in patients undergoing this treatment [36] . Last, training one arm in a hormonal milieu with 3-time more testosterone than the other arm has no effect on either myofibrillar protein synthesis rate, muscle hypertrophy, or strength changes that occur with training [37, 38] . Together, these data indicate that even though testosterone affects developmental processes that regulate muscle mass, physiological fluctuations (i.e., nonpharmacological-based changes) in testosterone have little effect on load-induced skeletal muscle hypertrophy.
Even though post-exercise testosterone does not affect load-induced skeletal muscle signaling, protein synthesis, or hypertrophy, there is no doubt that it and a whole host of other hormones go up both in the circulation [37, 39] and within the working muscle [40, 41] following resistance exercise. These hormones, like IGF-1 [42] and growth hormone [43, 44] can all affect developmental skeletal muscle mass and strength. However, it is clear from both in vitro work [45] , animal [42, [46] [47] [48] [49] , as well as human training studies [37, 38] that none of these hormones are required for load-induced skeletal muscle hypertrophy (explained in depth below). Therefore, even though hormones set our baseline muscle size and strength, they play little role in the adaptive response to resistance training.
Chalones
Chalones are tissue-specific secreted proteins that control organ size [50] . It is thought that each organ can secrete a distinct chalone that circulates through the body and inhibits the growth of that specific tissue. In many cases, these are N-substituted oligopeptides that can regulate genes involved in growth and differentiation [51] . However, skeletal muscle has a different kind of chalone protein known as myostatin [52] . Myostatin, or growth and differentiation factor 8, is a member of the transforming growth factor b (TGFb) family of hormones. Myostatin was originally cloned by McPherron and Lee as a highly conserved, muscle-specific, secreted protein [53] . True to its categorization as a chalone, when the protein was naturally absent, as in Belgian Blue and Piedmontese cattle or whippet dogs, the animals have an excessively muscled phenotype [53, 54] . Further, decreasing the receptor for myostatin, increasing the production of its propeptide (that inhibits myostatin-activin IIb receptor binding), or increasing the production of follistatin (a natural TGFb family inhibitor) results in an increase in muscle mass [55] . It is important to note that the increase in muscle mass due to inhibition of myostatin signaling early in development results in both hyperplasia and hypertrophy [52] . This is in contrast to what occurs following load-induced muscle growth, where muscle growth is primarily the result of skeletal muscle hypertrophy [9] . In fact, even though myostatin clearly plays a role in muscle mass, its role in loadinduced skeletal muscle hypertrophy is still equivocal. For example, even though 4 days of training decreases myostatin mRNA in proportion to the load across the muscle [56] , in human muscle myostatin mRNA goes down the most in ''non-responders,'' those subjects who do not increase muscle mass after resistance exercise [57] . Further, if a decrease in circulating myostatin drives load-induced hypertrophy, why do only the loaded muscles grow [26] and not every muscle in the body? These data suggest that myostatin mRNA may not be the best predictor of muscle growth or that myostatin protein may not be a true chalone following resistance exercise. However, as we learn more about the complexity of myostatin signaling, a novel molecular model for load-induced inhibition of myostatin signaling is beginning to become clear (discussed below).
Feeding
The consumption of sufficient nutrients is needed for developmental muscle growth. However, in energyrestricted diets that in all other manners are of high-quality (i.e., have sufficient protein) there is no long-term negative effect on muscle size or function relative to body mass [58] . In contrast, in the absence of sufficient protein, muscle does not develop to the proper size [59] . Therefore, protein is a key component of muscle development. In rats however, there is no effect of caloric restriction [60] or either increasing or decreasing dietary protein on muscle hypertrophy following prolonged overload [61] . This is in stark contrast to the role of protein in human load-induced skeletal muscle hypertrophy [2] . In humans, providing protein after resistance exercise leads to more myofibrillar protein synthesis and has the potential to decrease protein degradation [62] . Further, the consumption of protein together with resistance training leads to greater muscle hypertrophy than consumption of isoenergetic carbohydrate [63] , revealing that it is amino acids-not energy per se-that can augment protein accretion. After exercise, there is an increase in amino acid transport [64, 65] resulting in a concentration of the substrates for protein synthesis. Interestingly, this load-induced increase in amino acid sensitivity is maintained for at least 24 h following the completion of exercise [66] . The role of protein feeding in human load-induced muscle hypertrophy is so important that the amount [67] , type [68] , and timing of protein intake [69] after resistance exercise has been extensively studied. These studies allow us to state that the consumption of *0.25 g/kg body weight of a rapidly digested and leucine-rich protein source every 4-5 h throughout the day and soon after the completion of resistance exercise is needed to optimize load-induced skeletal muscle hypertrophy in humans.
The difference between the role of protein in rodent and human load-induced skeletal muscle hypertrophy is likely due to the extreme difference in the load itself and not a species difference. Many rodent studies use a synergist ablation model, whereby a large muscle is removed and the resulting intact muscles receive a constant mechanical stimulus to grow [46] . This is in stark contrast to human resistance exercise where subjects exercise intermittently several times per week resulting in a time under tension that is much lower. Together these data suggest that for an intermittent loading paradigm (human resistance training), the provision of sufficient amino acids at an optimal interval is essential for optimal loadinduced skeletal muscle hypertrophy. However, if the load is more chronic, the need for dietary amino acids to potentiate the effect of loading is reduced.
Catecholamines
Resistance exercise is a whole body stress. During resistance exercise, catecholamine levels rise significantly [70, 71] . Catecholamines bind to and activate adrenergic receptors [72] . With respect to skeletal muscle hypertrophy, the beta-2 (b2) adrenergic receptors receive the most attention due to the ability of b2-agonists to induce skeletal muscle hypertrophy [73] . Therefore, the potential of catecholamines, acting through b2 receptors to induce muscle hypertrophy is an attractive model. However, there has always been the issue of how a global stress signal, such as a rise in catecholamines, could result in a response only in the muscles that have performed resistance exercise. An attractive model to address this concern has been put forward by Bruno et al. [74] . In this model, calcium, released during exercise, converges with the b2-receptor to activate a downstream signaling cascade that drives skeletal muscle hypertrophy (see more detail below). With this new insight, the potential role of whole body stress, in the form of a rise in catecholamines, warrants serious consideration as a mechanism for load-induced muscle hypertrophy.
Molecular Signals Underlying Load-Induced Skeletal Muscle Hypertrophy mTORC1 and the Activation of Translation Initiation
On the foundation of a great deal of physiological research into skeletal muscle hypertrophy [8, 24-26, 46, 75] , in 1999 the first molecular regulator of load-induced skeletal muscle hypertrophy was identified [76] . The protein identified was a serine/threonine protein kinase called the mechanistic/ mammalian target of rapamycin (mTOR) [77] . Fifteen years later, we know that mTOR is an evolutionarily conserved protein kinase that is important in relaying information from nutrients, growth factors, and mechanical loading to drive protein synthesis and cell growth [77] . However, mTOR has limited kinase activity on its own [78] . Instead, mTOR forms complexes with other proteins that dictate its location, activity, and downstream targets. Currently, we know mTOR to exist within two complexes: complex 1 (mTORC1) and complex 2 (mTORC2). The primary components of complex 1 are the regulatory-associated protein of mTOR (raptor), the mammalian lethal with SEC13 protein (mLST8/GbL), the proline-rich akt substrate (PRAS40), and the DEP domain-containing mTOR-interacting protein (DEPTOR). Complex 2 contains the rapamycin insensitive companion of mTOR (rictor), mLST8/GbL, protein observed with Rictor-1 (PROTOR), DEPTOR, and MAP kinase interacting protein 1 (mSIN1). Complex 1 is rapamycin-sensitive and integral to controlling cell size, and will therefore be the focus of our discussion.
Over the last 5 years, the mechanisms underlying the activation of mTORC1 by amino acids, growth factors, and mechanical loading have been largely elucidated (see below). However, more work is needed before we fully understand the activation of mTORC1 and the identity of its downstream targets. The importance of mTORC1 in the regulation of muscle mass is seen by the fact that inhibiting mTORC1 in humans with the macrolide drug rapamycin has been shown to block acute amino acid- [79] and resistance exercise- [80] induced increases in muscle protein synthesis. Further, rapamycin blocks the hypertrophy that normally occurs after chronic mechanical loading [81] , an effect specific to decreased mTORC1 activity and not to off-target effects of the inhibitor [9] . Similarly, the constitutive genetic upregulation of mTORC1 activity results in muscle hypertrophy [82] and the increase in mTORC1 activity following a single bout of exercise correlates with the increase in muscle mass following training [76, 83] . Together these studies suggest that mTORC1 is a critical regulator of skeletal muscle cell size and that for us to understand load-induced skeletal muscle hypertrophy we must understand how mTORC1 is regulated.
Growth Factor Activation of mTORC1
The activity of mTORC1 is regulated by a number of pathways allowing for tight control of cell growth in concert with changes in cellular energy levels [84, 85] , the availability of nutrients [86, 88, 110] , tissue load [87] , and stress [77] . Of the various signaling pathways that activate mTORC1, the insulin/growth factor signaling pathway remains one of the best characterized, owing to its role in diabetes. In this context, mTORC1 becomes activated when it associates with the small G-protein Rheb (Ras homolog enriched in brain; Fig. 2 ). Following insulin/IGF1 binding to its receptor on the membrane, a series of events ensue that releases the inhibition of Rheb, resulting in increased mTORC1 activity [88] . Rheb-induced activation of mTORC1 is dependent on its GTP binding state, as GTP bound Rheb increases mTORC1 activity while GDP bound Rheb does not [89] . In the activation of mTORC1 by growth factors, a negative regulator of Rheb, called the TSC2 complex, is sequestered away from Rheb following insulin binding. The TSC2 complex is composed of hamartin (TSC1), tuberin (TSC2), and TBC1D7 [90] . The TSC2 complex acts as a GTPase activating enzyme (GAP) that keeps Rheb in the GDP bound state [91] . Following insulin treatment, TSC2 is phosphorylated by protein kinase B (PKB)/akt [92] resulting in its relocalization away from Rheb [88] . Akt not only inactivates the TSC2 complex, but also inhibits PRAS40 (proline-rich akt substrate of 40 kDa); a negative regulator of mTORC1 that directly inhibits the ability of mTOR to phosphorylate other targets [93] . Akt becomes activated as a direct result of the insulin/ growth factor-dependent movement of a series of proteins to the plasma membrane. When insulin binds to its receptor, the receptor autophosphorylates creating a docking site for the insulin receptor substrates 1/2 (IRS1/2) [94] . IRS1/2 then moves to the plasma membrane where it recruits the regulatory subunit of the phosphoinositide 3-kinase (PI3K) [94] . This brings PI3K to the membrane where it can phosphorylate its target, the membrane phospholipid phosphoinositol (4,5)-bisphosphate (PIP2). The resulting phosphoinositol (3,4,5)-trisphosphate (PIP3) then acts as a docking site in the plasma membrane for akt and its kinase the 3-phosphoinositide-dependent protein kinase-1 (PDK1) [95] . When akt and PDK1 co-localize at the membrane, PDK1 phosphorylates akt at one site [96] and the membrane-associated mTORC2 [97] phosphorylates a second site; resulting in full activation of akt and the subsequent phosphorylation of TSC2. In the end, this long complex pathway strives simply to move the TSC2 complex away from its target (Rheb) so that mTORC1 can be turned on (Fig. 2) . This same final step is shared by mechanical loading (see below) and this is why there is very little additive effect of both loading and growth factors. However, amino acids signal in a parallel fashion (described in detail below) and as a result amino acids can increase mTORC1 signaling when supplied together with either growth factors or loading.
Load-Induced Activation of mTORC1
The ability of rapamycin to inhibit the acute load-induced increase in muscle protein synthesis in humans [80] highlights the importance of mTORC1 in the response to mechanical loading. The exact mechanism underlying the transduction of the mechanical signal into increased mTORC1 activity remains relatively elusive. However, at least two distinct events appear to regulate mechanical loading mediated activation of mTORC1: an increase in the activity of Rheb [87] ; and an increase the abundance of phosphatidic acid [98] . The mechanism underlying these two events will be described below.
Recent work from Troy Hornberger's lab demonstrates that, like insulin and growth factors, loading results in the translocation of TSC2 away from Rheb [87] . In fact, Jacobs et al. were the first to show that the activation of mTORC1 by any stimulus was the result of the forced removal of TSC2 from Rheb [87] . In mouse muscle, at rest, TSC2 localizes with Rheb. Following resistance exercise, TSC2 becomes phosphorylated on RxRxxS*/T* residues and this phosphorylation event corresponds to the movement of TSC2 away from Rheb [87] . Therefore, just like insulin and growth factors the final step in the activation of mTORC1 is the phosphorylation of TSC2 (Fig. 3) .
However, unlike insulin and growth factors the kinase responsible for the phosphorylation of TSC2 in response to resistance exercise does not appear to be akt. This conclusion comes from data collected in a number of different labs using very different methods. First, Hornberger showed that stretching isolated muscles in the presence of the PI3K inhibitor wortmannin could completely block the activation of akt without altering mTORC1 activation [45] . He further showed that mTORC1 activation in response to loading occurred normally in muscles that lacked akt1 [45] . Second, Spangenberg et al. used a mouse model that carried a knockin mutation in the insulin receptor, that prevents the insulin/IGF1-induced activation of akt, to show that in response to load these animals turned on mTORC1 and their muscles grew normally [42] . Third, in most human studies akt phosphorylation is not related to the load across the muscle, but rather the feeding state. In fact, in many human resistance exercise studies akt phosphorylation decreases, despite mTORC1 activation [99] . Fourth, we have shown that following resistance exercise the recruitment of PI3K to the membrane and the activation of akt decreases in muscles where mTORC1 activity rises up to 80-fold. From these data, it is clear that while insulin and growth factors activate mTORC1 through akt, load induces an akt-independent activation of mTORC1. Since the end Fig. 2 The activation of the mechanistic target of rapamycin complex 1 (mTORC1) by growth factors. Growth factors bind to receptor tyrosine kinases that recruit the insulin receptor substrates (IRS1/2) and this brings PI3K to the membrane. When at the membrane, PI3K converts phosphoinositol (4,5)-bisphosphate (the two red circles at the membrane) into phosphoinositol (3,4,5)-trisphosphate (the three green circles at the membrane), which is a docking site for akt and its upstream kinase the 3-phosphoinositidedependent protein kinase-1 (PDK1). When akt and PDK1 co-localize at the membrane, PDK1 phosphorylates akt at one site and the membrane-associated mTORC2 phosphorylates a second site; resulting in full activation of akt. Active akt turns on mTORC1 by phosphorylating and removing PRAS40 and TSC2 from mTOR and Rheb, respectively result of both loading and growth factors is the movement of TSC2 away from Rheb, using different upstream kinases, this explains why loading and growth factors do not have an additive effect on muscle hypertrophy. While it remains unclear what mediates load-induced TSC2 phosphorylation, a number of potential candidates are currently being assessed.
The second direct activator of mTORC1 associated with load-induced muscle hypertrophy is a glycerophospholipid known as phosphatidic acid (PA). PA results in marked increases in mTORC1 activity when provided exogenously or through the transgenic overexpression of the enzymes that synthesize PA [100] . Similarly, limiting PA production results in a decrease in mTORC1 activity (for review see [98] ). PA is thought to mediate mTORC1 activation through direct binding to the FKBP12-rapamycin-binding domain of mTOR [100] . Mechanical loading of muscle results in increased production of PA and this is required for mTORC1 activation. Recently, diacylglycerol kinase zeta (DGKf), one of many enzymes responsible for the synthesis of PA, has been shown to play a role in loadinduced mTORC1 activation [98] . You et al. [100] demonstrated that DGKf activity increased biphasically with stretch and that adding more DGKf to muscle cells in vitro could increase the activation of mTORC1 by serum. Further, muscles from DGKf knockout mice did not show as great an increase in PA as wild type controls in response to stretch [100] . Last, electroporating DGKf into muscle resulted in the activation of mTORC1 and skeletal muscle hypertrophy, whereas the kinase dead DGKf did not [100] . These data suggest that DGKf is involved in the activation of mTORC1 in skeletal muscle in response to stretch. However, whether DGKf is required for load-induced activation of mTORC1 has yet to be determined. In fact, Fig. 3 The activation of the mechanistic target of rapamycin complex 1 (mTORC1) following resistance exercise and feeding. Lifting a heavy weight to failure stimulates a mechanoreceptor that in turn activates an RxRxxS*/T* kinase that phosphorylates and moves the tublerosclerosis complex (TSC2) away from the lysosome allowing Ras homologue enriched in brain (Rheb) to remain in the guanosine triphosphate (GTP) bound state. Simultaneously, amino acid uptake and intracellular amino acid levels increase. The extra amino acids stimulate folliculin to act as a GTPase activating protein (GAP) toward RagC/D and GAP activity toward Rags (GATOR) 2 blocks GATOR1 (the GAP of RagA/B) and the Ragulator GTP loads RagA/B and activates the complex. The active Rag complex then binds to raptor and positions mTOR beside its activator GTP bound Rheb. The resulting elevation of mTORC1 activity drives myofibrillar protein synthesis and eventually leads to an increase in muscle mass and strength. LAT1 L-type amino acid transporter, Rab7 Ras-related protein 7, LAMP2 lysosome-associated membrane protein 2, P phosphorylation, DEPTOR DEP domain-containing mTOR-interacting protein, GbL G-protein beta subunit-like protein, PRAS40 proline-rich Akt substrate of 40 kilodaltons, and RAPTOR the regulatoryassociated protein of mTOR the absolute activation of mTORC1 in response to load in the DGKf knockout muscles is the same as the wild type controls [100] , suggesting that even though DGKf can modulate mTORC1 activity, it is not required for the loadinduced activation of mTORC1.
Amino Acid Activation of mTORC1
Amino acids are thought to activate mTORC1 using a mechanism that is distinct from loading or growth factors; allowing for an additive effect of combining these stimuli (as discussed above). The initial evidence that amino acid activation of mTORC1 was growth factor and loadingindependent came from studies in TSC2 knockout cells. As described above, the removal of TSC2 by either loading or growth factors activates mTORC1. Therefore, in the absence of TSC2, basal mTORC1 activity is higher. Interestingly though, TSC2 knockout cells retain amino acid sensitivity [101] . Whether in the presence or absence of TSC2, amino acids are thought to regulate mTORC1 activity by the translocation of mTORC1 towards Rhebpositive membranes (review by [102] ). In amino acid deprived cells, mTORC1 is dispersed throughout the cytoplasm [103] . However, within minutes of the addition of amino acids, mTORC1 relocalizes to Rheb-positive membranes [104] . The importance of this translocation event was demonstrated by fusing raptor to the last 15 amino acids of Rheb (Raptor-Rheb15). This fusion protein resulted in constitutively active mTORC1 that was insensitive to amino acid withdrawal [105] . In contrast, the fusion of raptor to Rheb via the CAAX Box, a site that normally acts to anchor Rheb to the membrane, was not able to activate mTORC1 during amino acid withdrawal. These data demonstrate that amino acid-mediated activation of mTORC1 requires only the association of mTORC1 with Rheb and the localization of these proteins to the lysosome [105] . The importance of lysosomal localization of mTORC1 and Rheb can be attributed to additional regulators of mTORC1 at the lysosome surface of these cells. Included in the proteins that regulate mTORC1 at the lysosome in dividing cells are the Ragulator, the tumor suppressor folliculin and the Rag family of small G-proteins.
The Rags are a family of four small G-proteins denoted, RagA, B, C, and D, that exist as heterodimers consisting of one RagA or B bound to one RagC or D [106] . The Rag heterodimers localize to the lysosomal membrane via the Ragulator and interact with mTORC1 via direct binding to raptor [103, 107] . The interaction between RagA/B and raptor is dependent on the GTP loading of the Rag heterodimer, which in turn is regulated by a series of GAP and GEF proteins that are sensitive to nutrients [103, 110] . Loss and gain of function studies have demonstrated that the knockdown of Rag or the overexpression of a dominant negative form of the Rags suppresses the effects of amino acids on mTORC1 activity [107] . Conversely, a constitutively active Rag heterodimer (RagB GTP /RagD GDP ) relocalized mTORC1 to Rheb-positive membranes, and thereby activated mTORC1, in a leucine-independent manner [103] . These data suggest that the Rags mediate mTORC1 movement to the lysosome, whereupon Rheb can then activate mTORC1 [103] .
Nutrient regulation of Rag activity, while still in its infancy, is believed to involve two complexes of proteins; one called the Ragulator [105] and the other GATOR [108] . The Ragulator is tethered adjacent to Rheb at the lysosomal membrane and exhibits amino acid-dependent guanine nucleotide exchange factor (GEF) activity toward RagA/B [105, 109] . The GEF activity of the Ragulator complex is regulated by the vacuolar H ? -adenosine triphosphatase ATPase (v-ATPase) [110] . The v-ATPase is a multi-protein complex that has been primarily characterized for its role in the acidification of the lysosomal lumen [111] . However, the inhibition of v-ATPase activity also impairs amino acid-induced mTORC1 localization at the lysosome and S6K1 phosphorylation [112] . The underlying mechanism appears to be that low amino acid concentrations within the lysosomal lumen are sensed by the v-ATPase resulting in a conformational change that alters the interaction between the v-ATPase and the Ragulator resulting in the loss of GEF activity toward RagA/B [112] for further review see [102] .
Recently, a number of proteins that may have GAP activity toward the Rag proteins have been discovered including GATOR1, folliculin, and the leucyl tRNA synthase. In the absence of amino acids, RagA/B is held in the inactive GDP bound state by the heterotrimeric GAP protein complex GATOR1 [108] . When amino acids are high, the GATOR2 complex moves the GATOR1 complex away from the Rags thereby removing the GAP activity toward RagA/B [108] . The Ragulator complex then acts as a GEF toward RagA/B activating this half of the heterodimer [109] . Meanwhile, either the tumor suppressor folliculin or the leucyl tRNA synthase (LRS) acts as a GAP toward RagC/D [113, 114] . If the LRS is the GAP, this would provide the importance of leucine that we see in muscle following resistance exercise. However, there is some question as to whether the LRS can perform this role in vivo [108] . Furthermore, treatment of mouse embryonic fibroblasts with a mixture of amino acids devoid of leucine, blocks signaling downstream of mTORC1 without affecting mTORC1 association with the lysosome [115] . These data suggest that folliculin is the RagC/D GAP and that leucine affects mTORC1 signaling in a separate manner. Regardless, once RagA/B is GTP bound and RagC/D is GDP bound, the Rag heterodimer can bind to raptor and through its connection with the Ragulator recruits mTORC1 to the lysosome [105] where it can be activated by the association with GTP bound Rheb [91] .
None of this detail of nutrient signaling is known to occur in muscle following exercise. However, we do know that intracellular amino acid levels (leucine in particular) increase acutely after strength exercise [64, 65] , possibly due to an increase in amino acid transporters, including the primary leucine transporter in muscle LAT1 [116, 117] . The accumulation of amino acids following strength exercise activates vesicular trafficking protein (VPS) 34 [65] , a kinase that promotes the movement of membrane vesicles, like the lysosome [118] . The activation of Vps34 by amino acids after resistance exercise likely facilitates the movement of lysosomal membranes to further promote the interaction of mTORC1 with the Rag-Ragulator complex.
Even though it is clear that the Rag proteins are necessary for mTORC1 activation by amino acids, the role of Rag GTP loading in the activation of mTORC1 has recently been questioned [119] . Prof. Joseph Avruch's group has demonstrated that the amount of GTP bound RagA/B was not changed by amino acid withdrawal and that GTP loading did not alter mTORC1 association [119] . These authors showed that GTP loading of the Rag heterodimer was rapid, insensitive to amino acid withdrawal, and that the Rags have very low intrinsic GTPase activity. Further, using a specific inactivating mutation in the Rag, that prevents GTP loading of RagA/B, did not interfere with amino acid-mediated mTORC1 binding to the lysosome or activation [119] . Even though the data from Oshiro et al. argues that the GTP bound state of Rag is inconsequential for the activation of mTORC1, they show that the Rag heterodimer is still required for mTORC1 activation by amino acids. The differences shown in this paper suggest the requirement of an as yet unidentified protein that is required for the activation of mTORC1 by the Rag heterodimer. Whether this protein is absent in HeLa cells (the previous studies were performed in HEK293 cells) or there is some other explanation, it is clear that further work is needed to fully understand how amino acids activate mTORC1 and even more work needs to determine which of these processes are at work in muscle following resistance exercise.
Smad2/3 Transcriptional Activity and Growth
As discussed above, the myostatin/TGFb signaling pathway can limit developmental muscle size and strength. The TGFb family of ligands that activate this pathway, such as myostatin, TGFb, or Activin, activate receptors that are coupled to a class of effector molecules known as the small mother of decapentaplegic (Smad) proteins [120] . Smad proteins are transcription factors that can directly regulate hundreds of gene targets, many of which are involved in muscle growth [121] and wasting [53] . Myostatin, like insulin, binds to a receptor tyrosine kinase in the membrane of the muscle cell [122] to exert biological action (Fig. 4) , predominantly through receptor-activated Smad2 and/or Smad3 (Smad2/3). The phosphorylation of either Smad2 or 3 by the Activin IIB and ALK4/5/7 co-receptors, as a result of myostatin binding, changes the conformation of the Smad allowing it to bind to the common mediator Smad4 [123] . Upon Smad2 or 3 binding to Smad4, the complex translocates to the nucleus where it can directly modulate gene expression [121] or modulate chromatin structure to more broadly decrease the expression of genes associated with muscle growth [123] .
Beyond the classical TGFb signaling pathway that takes Smad2/3 into the nucleus to alter transcription (Fig. 4) , the phosphorylation of Smad2/3 also appears to directly affect akt [124] . Winbanks et al. have shown that the myostatin inhibitor follistatin can increase PIP3 levels in the membrane resulting in an increase in akt phosphorylation and the activation of mTORC1 [124] . Thus, high myostatin levels lead to phosphorylation of Smad2/3, inhibition of akt phosphorylation, and low mTORC1 activity. This inhibition of mTORC1 by myostatin is a consistent finding across models [124] [125] [126] and as a result the mTORC1 inhibitor rapamycin is able to block approximately half of the increase in muscle mass seen with myostatin inhibition [124, 127] . However, the other half of the muscle growth cannot be explained by the activation of mTORC1 and points to the importance of the transcriptional regulation of Smad2/3.
As mentioned above, the transcriptional role of Smad2/3 signaling requires Smad2/3 translocation into the nucleus with Smad4. The importance of this step has been highlighted by two recent reports showing that a separate group of Smad proteins, the receptor-activated Smad1/5/8 family, can modulate Smad2/3 activity. In the first report, Sartori et al. [128] used transgenic mouse models to demonstrate that association with Smad4 was a limiting step in the regulation of muscle mass by myostatin. They achieved this by showing that inhibition of Smad1/5/8 increased denervation-mediated muscle wasting. The increase in wasting corresponded with increased amounts of Smad2/3 binding to Smad4 and translocation into the nucleus, whereas increasing activated Smad1/5/8 prevented the negative regulation of muscle mass by myostatin. Almost at the same time, Winbanks et al. used adeno-associated viral vectors (AAVs) to activate Smad1/5/8, and showed that this resulted in significant muscle growth in adult mice [129] . AAV-mediated overexpression of bone morphogenetic protein (BMP) 7 or introduction of a constitutively active ALK3 (both of which activate Smad1/5/8) was sufficient to promote muscle growth. Additionally, AAV-mediated overexpression of the endogenous Smad1/5/8 inhibitor, Smad6, blocked the ability of follistatin to drive muscle growth [129] . Together, these studies demonstrate that the ability of myostatin to regulate muscle growth is dependent on competition for Smad4 binding. When myostatin signaling is high, Smad4 binds to Smad2/3 and this shuttles Smad2/3 into the nucleus where it can decrease the expression of genes needed for muscle growth and/or increase the expression of genes that drive muscle wasting. When BMP signaling is high, Smad4 shifts binding toward Smad1/5/8 and this either results in the targeting of a different set of genes or reverses the expression effects of myostatin.
While these pathways clearly play an important role in developmental muscle growth, their role in load-induced muscle growth remains equivocal. As described above, myostatin mRNA levels do not predict load-induced skeletal muscle hypertrophy [57] . Furthermore, we have not seen changes in Smad2/3 [130] or Smad1/5/8 (Aguirre et al. in preparation) phosphorylation following resistance exercise. In spite of the absence of differences in Smad phosphorylation, the expression of a Smad2/3 inhibited mRNA increases in proportion to the degree of muscle hypertrophy following training [130] . This suggests that following resistance exercise there is a decrease in Smad2/ 3 transcriptional activity. One possible explanation for this observation is that the Smad2/3 transcriptional inhibitor Notch is activated following resistance exercise [130] . In this model, resistance exercise causes the cleavage of the intracellular domain of Notch at the plasma membrane (Fig. 4) . Active Notch then moves to the nucleus where it acts as an activator of transcription and also decreases the transcriptional repression of Smad2/3 [131] [132] [133] . In this way, Smad activity can be regulated locally within the exercised muscle, resulting in a muscle-specific signal for load-induced skeletal muscle hypertrophy.
G-Protein-Coupled Receptors as Signalers of Muscle Activity
As discussed above, the stress of resistance exercise can be signaled in part through the activation of b2-adrenergic receptors. The b2 receptor is one member of a large class of G-protein-coupled receptors (GPCR). There are over 800 distinct GPCRs encoded in the human genome, making this the largest family of signaling receptors in our bodies [134] . Fig. 4 The role of Smads in the control of muscle mass. Myostatin and similar members of the TGFb superfamily can phosphorylate Smad2/3 allowing it to bind to the common mediator Smad4 and move to the nucleus. In the nucleus, Smad2/3 drives transcriptional events that result in the transcription of genes that limit muscle size. Smad2/3 signaling can be competitively inhibited at the level of Smad4 binding by Smad1/5/8. BMP7 and other members of the TGFb superfamily activate Smad1/5/8 through ALK3 and the BMP receptor. Resistance exercise can also limit Smad2/3 signaling by cleaving and activating Notch. The intracellular domain of Notch then moves to the nucleus and blocks Smad2/3 transcription On top of the structural diversity of this family of signaling proteins lies their functional selectivity, meaning that the output of the receptor is not simply determined by the binding of an agonist, but also the context of the cellular environment [135] . As discussed above, functional selectivity may explain the ability of epinephrine to turn on growth-related proteins only in the exercised muscles [74] . In this example, whole body stress increases catecholamine levels resulting in increased binding to the b2-adrenergic receptor. In the working muscle, there is a concomitant increase in calcium as a direct result of contraction. When both of these signals are present in the same cell, the cyclic-AMP response elementbinding protein (CREB)-regulated transcriptional co-activator (CRTC) is activated [74] and the activation of this protein can drive skeletal muscle hypertrophy. However, if epinephrine can only drive growth in an activated (calcium-rich) environment, how is it that other b2 agonists, such as clenbuterol, formoterol, and salmeterol can drive growth in all muscles regardless of activity [73] ? This could potentially be explained by the ability of these drugs to simultaneously alter calcium homeostasis, increasing the passive release of calcium from the sarcoplasmic reticulum within the muscle without the need for exercise [136, 137] . In fact, much of the growth response to b2 agonists can be blocked by altering calcium-activated signals within muscle [138] . Together, these data suggest that GPCR activation, in a calcium-rich environment, can signal through CRTC to increase muscle mass.
The b2-adrenergic receptor is not the only GPCR that can induce skeletal muscle growth. Distinct GPCRs that are activated by Wnt [139] , ghrelin [140] , PGC1a4 [141] , and lysophosphatidic acid [142] can all increase muscle mass or prevent muscle atrophy. Interestingly, the ability of GPCRs to alter muscle mass is dependent on mTORC1 since inactivation of mTORC1 by rapamycin prevents G-protein coupled muscle hypertrophy [139, 143] . Furthermore, the molecular explanation for muscle hypertrophy for many of the GPCR agonists seems to be through the upregulation of IGF-1 and the activation of the PI3K/akt/mTORC1 canonical growth factor pathway [74, 139, 142] . As discussed above, this pathway plays a limited role in load-induced skeletal muscle hypertrophy, suggesting that GPCRs may be more important for developmental growth and likely play a limited role in the adaptation to resistance exercise. However, this class of proteins may provide muscle-specific targets for the development of pharmacological interventions to increase muscle mass and strength.
Conclusions
In adults, increases in skeletal muscle mass are dependent on the load across the muscle. In the past 15 years, we have learned a great deal about the acute response to an increase in load across a muscle. However, this understanding is far from complete. For example, even though the acute activation of mTORC1 is needed to increase muscle protein synthesis after resistance exercise [80] , in humans, longterm muscle growth is inversely related to mTORC1 transcriptional activity [144] . Therefore, it is clear that we have a long way to go before we completely understand how a mechanical signal (load on a muscle) is converted to a chemical signal (mTORC1 activation or Smad2/3 inhibition) that can change muscle phenotype (bigger/stronger muscles). As a result, the creation of a drug that can mimic the effects of resistance exercise on skeletal muscle mass and strength is many years in the future.
